By Fineline Cube 
Germany-based multinational Merck KGaA (ETR: MRK) reported Q2 2025 financial results, which were significantly affected by the depreciation of the US dollar against the Euro. Net sales decreased by 1.8% year-on-year (YOY) to EUR 5.25 billion (USD 6.12 billion). Excluding foreign exchange effects, sales increased by 2% YOY. EBITDA profits rose 4.6% YOY organically to EUR 1.5 billion but fell by -8.5% due to currency impacts.
Business Unit Performance
- Life Sciences: Sales increased by 3.7% organically and 0.4% YOY including foreign exchange effects, reaching EUR 2.3 billion (USD 2.7 billion). Process Solutions was the major growth driver with 11.5% organic growth.
- Healthcare: Achieved 3.6% organic growth (-1.6% including currency effects) to EUR 2.1 billion (USD 2.5 billion). Key drug sales showed strong performance:
- Erbitux (cetuximab): +10.9% growth.
- Mavenclad (cladribine): +20.7% growth.
- Pergoveris (follitropin alfa / lutropin alfa): +20.5% growth.
- Electronics: Sales declined by 7.4% to EUR 886 million (USD 1,032 million), despite ongoing demand growth for Semiconductor Materials.
SpringWorks Acquisition
Merck completed the USD 3.4 billion acquisition of US-based SpringWorks Therapeutics in July. The company expects revenue contributions from SpringWorks’ rare disease portfolio, including the recent European approval of Ezmekly (mirdametinib) for symptomatic, inoperable plexiform neurofibromas.-Fineline Info & Tech